Thought Control, Spinal Repair & China’s 2030 BCI Roadmap: The Next Frontier of Neurotech – Issue #27
Welcome to Neurotech Pulse – Issue #27! In this edition, we explore the latest advancements shaping neurotechnology.
From Neuralink’s first patient update and Stanford’s inner-speech decoder to Israel’s upcoming spinal cord transplant, the boundaries of brain–machine medicine are expanding fast. Funding highlights include Neurovalens, Jocasta Neuroscience, and SetPoint Medical, fueling growth across non-invasive stimulation, longevity therapeutics, and neuroimmune therapies. This issue’s Case Study Spotlight turns to Precision Neuroscience, whose Layer 7 Cortical Interface offers a minimally invasive, high-resolution path to scalable BCIs. We also dive into China’s 2030 BCI roadmap, CorTec’s wireless stroke-rehab implant, and new frontiers in sleep and pain treatment.
⚡️Neurotech Newsflash
Neuralink’s First Patient Shares Update: 18 months post-surgery, Noland Arbaugh says the brain implant lets him study, game, and control devices by thought, restoring independence after paralysis. (Read more)
BCI Decodes Inner Speech on Command: A Stanford-led team built a brain-computer interface that can decode inner monologues with up to 74% accuracy. The system only activates with a chosen keyword, protecting mental privacy while enabling communication for people with severe paralysis. (Read more)
Sam Altman Eyes BCI Startup to Rival Neuralink: Altman is reportedly co-founding Merge Labs, a brain-computer interface venture valued at ~$850M, with possible backing from OpenAI. Still early, it positions Altman against Musk in the race for human–AI integration. (Read more)
Israel Prepares for World’s First Spinal Cord Transplant: Tel Aviv University will attempt the first human spinal cord implant using lab-grown tissue from a patient’s own cells. Approved for compassionate use in eight patients, the approach has restored mobility in paralyzed animals. (Read more)
FDA Clears ONWARD Medical Spinal Study: The FDA has approved ONWARD’s Empower BP trial to test its ARC-IM implant, a neurostimulation device aimed at stabilizing blood pressure in spinal cord injury patients. Enrollment at ~20 sites will begin by late 2025. (Read more)
Synchron Moves Toward Pilot Study: After showing an ALS patient controlling an iPad with thought alone, Synchron is advancing its fully wireless Stentrode into a pilot study, with pivotal trials expected in 2026. (Read more)
💰Notable Funding
Neurovalens Raises £6M for Global Expansion: Belfast-based Neurovalens secured £6M (€6.95M) to scale its FDA-cleared neurostimulation devices for insomnia and anxiety, and to pursue approvals for PTSD treatment in the U.S. and beyond. (Read more)
Jocasta Neuroscience Raises $35M Series A: Arizona-based Jocasta Neuroscience secured $35M to advance its longevity protein α-Klotho (JN-0413) into Phase 1 trials for cognitive decline in neurodegenerative diseases, with IND submission planned for late 2026. (Read more)
SetPoint Medical Raises $140M: SetPoint Medical secured $140M to commercialize its FDA-approved neuroimmune therapy for rheumatoid arthritis and expand into other autoimmune conditions. (Read more)
🧠 Neurotech Trends:
China Unveils 2030 Roadmap to Lead Global BCI Industry: Seven government agencies, including MIIT, have released national guidelines to make China a world leader in brain-computer interfaces by 2030. The plan sets milestones for 2027 (breakthroughs in electrodes, chips, and integrated systems with international standards) and 2030 (2–3 globally influential enterprises, industrial clusters, and advanced business models). Both implantable and wearable BCIs are targeted, with lighter, faster devices, precision surgical robots, and next-gen BCI chips highlighted as priorities. Stock markets responded quickly, with BCI-linked companies in Hong Kong seeing double-digit gains. (Read more)
Sleep Apnea Implant Gains FDA Approval Amid Patent Clash: Nyxoah’s Genio system, a battery-free implant that stimulates hypoglossal nerves to keep airways open, has received FDA approval as an alternative to CPAP for obstructive sleep apnea. In trials, it reduced apnea episodes by 71%, but its U.S. launch faces a roadblock: rival Inspire Medical has filed a patent suit seeking to block entry. With ~30M Americans affected by OSA, the ruling could shape the competitive landscape of sleep neurotech. (Read more)
CorTec Begins First Human Trial of Wireless Stroke Rehab Implant: Germany’s CorTec has implanted its fully wireless Brain Interchange BCI in a stroke patient, testing whether cortical stimulation combined with physiotherapy can restore hand and arm movement. The device records brain signals, delivers targeted stimulation, and charges wirelessly through the skin, reducing infection risks tied to connectors. Early safety results will guide expansion to more patients, with pivotal trials targeted for 2027. (Read more)
📘 Neurotech Articles:
AI Cuts Stroke Diagnosis Time in UK Hospitals: Russells Hall Hospital in England has deployed RapidAI to speed up stroke triage, sending brain scans directly to consultants’ phones within seconds. The system shortens diagnosis by up to an hour, enabling faster treatment decisions and even detecting strokes in patients without typical symptoms. The rollout is part of the UK’s broader plan to integrate AI across the NHS. (Read more)
Targeting Pain Without Opioids: Amygdala Neurons Offer a New Path
Researchers at UNC, Stanford, and UCSF have pinpointed specific neurons in the amygdala that make pain feel unpleasant, thereby separating suffering from sensation. With a new $12M NIH grant, they’re developing small molecules to block these circuits without addictive opioid effects. Still in preclinical stages, the approach could transform chronic pain management by focusing on the brain’s emotional processing of pain rather than its sensory detection. (Read more)Smartwatches Detect Parkinson’s Earlier Than Clinical Scores: A study from Dr. Cynthia Sandor’s team (UK DRI at Imperial) shows that long-term smartwatch data can detect early Parkinson’s-related brain changes with higher sensitivity than gold-standard clinical risk scores. Using data from the Michael J. Fox Foundation’s PPMI cohort, researchers developed a digital risk score from sleep, heart rate, and activity patterns. When combined with smell testing, the model identified over 80% of individuals with abnormal brain scans or spinal fluid markers, offering a non-invasive, low-cost tool for early screening. (Read more)
🌐 Neurotech Edu. and Events:
MiNT UK 2025: Neurotechnology in Practice – Measuring Impact on Patient Outcomes
📅 Date: October 16, 2025 | 📍 CentrEd at ExCeL, LondonWhy Attend the Event?
Join clinicians, researchers, and innovators for a full-day conference on how neurotechnology is transforming clinical practice and patient outcomes. The program includes expert panels, interactive workshops, and poster sessions covering applications in neurorehabilitation, therapy, and beyond.Link to register: Register here
IEEE Brain Discovery and Neurotechnology Workshop
📅 Date: September 12–13, 2025 | Morris J. Wosk Centre for Dialogue, VancouverWhy Attend the Event?
Join global researchers and clinicians to explore breakthroughs in neurotechnology, machine learning for brain discovery, and clinical impact. The workshop features keynotes, panels on ethics and standards, and sessions highlighting future growth areas in neuroengineering.Link to register: Register here
🎬Case Studies
🎬 Case Study Spotlight: Precision Neuroscience – The Layer 7 Cortical Interface
In this edition’s case study spotlight, we highlight Precision Neuroscience, a rapidly advancing BCI company co-founded by former Neuralink engineer Dr. Ben Rapoport. Precision is developing the Layer 7 Cortical Interface, a thin-film electrode array that conforms to the surface of the brain, enabling thousands of channels of high-resolution recording and stimulation through a minimally invasive, reversible procedure. With FDA clearance secured in 2025 and early clinical trials underway, Precision is positioning its system as a safer, scalable alternative to penetrating implants.
Overview: The Layer 7 Cortical Interface is a flexible, modular array, 1/5th the thickness of a human hair, engineered to capture neural activity at the micron scale without damaging cortical tissue. Using a patented cranial micro-slit technique, the array can be placed on the brain’s surface within minutes and removed if needed. Each array contains 1,024 electrodes, and multiple arrays can be combined to cover larger regions of the cortex. The system is fully implantable, powered through inductive charging, and paired with machine learning software to decode neural intent and deliver precise bidirectional stimulation.
Use Case Highlights:
Restoring Communication & Independence: Enables patients with paralysis (e.g., ALS, SCI) to control digital devices like computers, tablets, smart home systems through thought alone.
Neurorehabilitation: Combines stimulation with physical therapy to promote neuroplasticity in stroke recovery.
Bidirectional Recording & Stimulation: Provides both neural signal capture and targeted stimulation, laying the groundwork for adaptive therapies in conditions such as refractory depression and epilepsy.
High-Resolution Neural Research: Offers researchers unprecedented micron-scale data density for mapping and decoding brain activity across regions.
Target Audience:
Patients with severe paralysis and neurodegenerative conditions
Neurosurgeons and clinicians specializing in stroke, epilepsy, and movement disorders
Research institutions advancing cortical recording and stimulation methods
Biotech and medtech partners developing BCI-driven therapies
Key Partnerships:
Precision is working with top academic hospitals and research institutes in the U.S. to conduct first-in-human trials and expand its clinical research footprint. In parallel, the company has invested in dedicated microfabrication facilities to strengthen control over its technology development.
Leadership Team:
Precision is led by neurosurgeon and BCI pioneer Dr. Ben Rapoport (Co-founder & CSO) and business builder Michael Mager (Co-founder & CEO), supported by a multidisciplinary team with expertise spanning neurosurgery, AI, chip design, and clinical translation.
For more information about Precision Neuroscience and the Layer 7 Cortical Interface, visit precisionneuro.io.
🌟 Neurotech Pulse Special Edition: Call for Contributions!
Calling all researchers and writers! Want to showcase your work in our upcoming Neurotech Insights edition? Reach over 10,000+ neurotech enthusiasts by sharing your innovative research. Submit your details and work to saman.nawaz@nexstem.ai
❤️ Join us on Discord.
Thanks for reading Neurotech Pulse! Subscribe for free to receive new posts.